Thus, ERRα depletion as well as C29 treatment elevated the mRNA and protein levels of Fbxw7 (Supplementary Fig. 9c–f), further indicating the benefits of ERRα inhibition for NASH treatment. This evidence concerns the gene FBXW7 and metabolic dysfunction-associated steatohepatitis.